For example, IDH‐mutant glioma patients treated with adjuvant chemoradiotherapy combined with the IDH inhibitor vorasidenib demonstrate significantly prolonged progression‐free survival and improved neurocognitive outcomes [119]. This evidence concerns the gene IDH1 and central nervous system cancer.